New Studies:
“Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA”
Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com
https://clinicaltrials.gov/ct2/show/NCT02348606?term=jazz&rank=15″
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com
https://clinicaltrials.gov/ct2/show/study/NCT02284568?term=teva%2C+ppms&rank=1&show_locs=Y#locn
Phase 3 Study of RPC1063 in Relapsing MS
Clinical Coordinator – LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com
https://clinicaltrials.gov/ct2/show/study/NCT02294058?term=receptos&rank=1&show_locs=Y#locn
Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Clinical Coordinator – LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com
https://clinicaltrials.gov/ct2/show/NCT02073279?term=chugai&rank=1
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
clinical Coordinator –LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com
http://www.clinicaltrial.gov/ct2/show/NCT01633112?term=CFTY720D2312&rank=1
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (MS): An Open Label, Long Term, Safety Trial
Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com
http://http://www.clinicaltrial.gov/ct2/show/NCT01797185?term=CLR_09_21&rank=1
http://www.clinicaltrial.gov/ct2/show/NCT01442194?term=Novartis+Passage&rank=1
